key: cord-0299563-xoqya9pl authors: Nuermberger, Eric L.; Martínez-Martínez, Maria Santos; Sanz, Olalla; Urones, Beatriz; Esquivias, Jorge; Soni, Heena; Tasneen, Rokeya; Tyagi, Sandeep; Li, Si-Yang; Converse, Paul J.; Boshoff, Helena I.; Robertson, Gregory T; Besra, Gurdyal S; Abrahams, Katherine A.; Upton, Anna M; Mdluli, Khisimuzi; Boyle, Gary W; Turner, Sam; Fotouhi, Nader; Cammack, Nicholas C.; Siles, Juan Miguel; Alonso, Marta; Escribano, Jaime; Lelievre, Joel; Pérez-Herrán, Esther; Bates, Robert H.; Maher-Ewards, Gareth; Barros, David; Ballell, Lluís; Jiménez, Elena title: GSK2556286 is a novel antitubercular drug candidate effective in vivo with the potential to shorten tuberculosis treatment date: 2022-02-05 journal: bioRxiv DOI: 10.1101/2022.02.04.479214 sha: cf01e333a3971aabd9f16815239008e69cd7a0a2 doc_id: 299563 cord_uid: xoqya9pl As a result of a high-throughput compound screening campaign of Mycobacterium tuberculosis infected macrophages, a new preclinical drug candidate for the treatment of tuberculosis has been identified. GSK2556286 inhibits growth within human macrophages (IC50 = 0.07 µM), is active against extracellular bacteria in cholesterol-containing culture media and exhibits no cross-resistance with known antitubercular drugs. In addition, it has shown efficacy in different mouse models of tuberculosis (TB) and has an adequate safety profile in two preclinical species. These features indicate a compound with a novel mode of action, although still not fully defined, that is effective against both multidrug or extensively-resistant (M/XDR) and drug-sensitive (DS) M. tuberculosis with the potential to shorten the duration of treatment in novel combination drug regimens. One Sentence Summary GSK2556286 is a novel preclinical drug candidate for the treatment of tuberculosis with a new mode of action potentially able to contribute to the shortening of TB chemotherapy. To date, virtually all approved drugs used to treat TB were identified through 73 phenotypic screens against actively replicating Mycobacterium tuberculosis in artificial 74 nutrient-rich media, or they were repurposed from other infectious indications (2). The first-75 line TB drug pyrazinamide (Z) is the notable exception, having been identified by screening 76 for activity in a murine TB model (3, 4) . Few other pathogens rival M. tuberculosis in their 77 ability to adapt to and persist within the infected host. Alternative screening methodologies that Over the last decade, we and others hypothesized that the macrophage, as a primary with the potential to shorten the duration of treatment in novel combination regimens for drug-99 susceptible and drug-resistant TB. Microbiological profile 102 To identify compounds that effectively inhibit intracellular growth of M. tuberculosis, 103 we screened a library of compounds against bacteria residing within human (THP-1) 104 macrophage-like differentiated monocytes. The exploitation of this screening approach led to 105 the identification of GSK2556286 (Fig. 1 ), a compound with potent activity (Table 1) Table S5 ). Pharmacokinetics of GSK2556286 after intravenous and oral administration at various 204 doses were evaluated in rodents and dogs. The compound exhibited low-to-moderate blood 205 clearance, as predicted by CLint in hepatocytes, and moderate volume of distribution. Absorption was rapid and oral bioavailability at pharmacologically relevant doses was high in 207 mice and moderate in rats and dogs, in agreement with the expected first-pass effect 208 (Supplemental Table S6 ) 209 Human PK parameters were calculated for GSK2556286 using a physiologically-based 210 pharmacokinetic (PBPK) modelling approach (GastroPlus), based on physicopchemical, 211 preclinical (in vitro and in vivo) and in vitro juman data. The PBPK models accurately 212 predicted the IV and oral PK data from preclinical studies in mice, rats and dogs, and the 213 prediction estimates a low human blood clearance (3.3 mL/min/kg), a moderate volume of 214 distribution (3.5 L/kg) and high oral bioavailability (≥ 60% for predicted clinical doses). Taking 215 as a reference the minimum AUC and Cmax at 10 mg/kg associated with a maximum effect as 216 a single drug in BALB/c mice, it was predicted a dose in humans between 150 and 300 mg/day 217 administration (based on targeting AUC and Cmax, respectively). To assess the risk of drug-drug interactions, direct inhibition of CYP isoforms was Table 225 S7 3 months of treatment to achieve a relapse rate lower than RHZ for 4 months. The proportions of mice relapsing after 2 and 3 months of treatment with BPaL, BPa+GSK2556286 and BPaL+GSK2556286 did not significantly differ, indicating that 312 GSK2556286 could replace L in the BPaL regimen without loss of efficacy. On the other hand, PaL+GSK2556286 was associated with significantly more relapses (p<0.0001) at all time 314 points and BL+GSK2556286 was associated with more relapses (p=0.0005) after 2 months of 315 treatment but was similar after 3 and 4 months. pretomanid and linezolid, GSK2556286 and isoniazid were formulated as described above. Other drugs were formulated and administered at the indicated dose as previously described Homogenates from mice receiving drug combinations were plated on the same agar media but 530 with the addition of activated charcoal powder (0.4%w/v) to prevent carryover of bedaquiline. Colonies were counted after 4 and 6 weeks of incubation at 37°C to ensure all cultivable 532 bacteria would be detected. Relapse after 2, 3 and 4 months of treatment with drug 533 combinations was assessed by holding cohorts of 15 mice per group for an additional 3 months 534 without treatment before sacrificing the mice and plating the entire lung homogenate, as 535 described above. Relapse was defined by detection of ≥ 1 CFU. Statistical analysis. CFU counts (x) were log-transformed (as x+1) before analysis. Group approximately 80% power to detect 40 percentage point differences in the relapse rate, after 544 setting alpha at 0.01 to adjust for up to 5 simultaneous two-sided comparisons. Smaller 545 differences may not be meaningful in terms of shortening the duration of treatment. Data will be made publicly available upon publication and upon request for peer review. Global Tuberculosis Report 2020. World Health Organization, 2020. Geneva Inhibiting Mycobacterium tuberculosis within and without Williams 572 JH. 1952. Experimental Chemotherapy of Tuberculosis. II. The Synthesis of 573 Pyrazinamides and Related Compounds The effect of 575 pyrazinamide (aldinamide) on experimental tuberculosis in mice In vitro drug discovery models for Mycobacterium tuberculosis 578 relevant for host infection High 583 content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for 584 intracellular antimycobacterial inhibitors Telacebec (Q203) Antituberculosis Agent Discovery of Q203, a 594 potent clinical candidate for the treatment of tuberculosis Novel 597 inhibitors of cholesterol degradation in Mycobacterium tuberculosis reveal how the 598 bacterium's metabolism is constrained by the intracellular environment Mycobacterial persistence requires the utilization of 601 host cholesterol Intracellular Mycobacterium 603 tuberculosis exploits host-derived fatty acids to limit metabolic stress. The Journal of 604 Biological Chemistry A Refined Developability Classification 607 Dose-ranging comparison of 610 rifampin and rifapentine in two pathologically distinct murine models of tuberculosis Evaluation of a mouse model 613 of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against 614 Mycobacterium tuberculosis Preclinical Efficacy Testing of New Drug Candidates Tuberculosis and the Tubercle Bacillus 2 nd Edition (CH 13 Treatment of Highly Drug-621 Resistant Pulmonary Tuberculosis Contribution of Oxazolidinones to 624 the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse 625 Model of Tuberculosis Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline Sterilizing activities of novel combinations 632 lacking first-and second-line drugs in a murine model of tuberculosis Rv1625c inhibits growth of Mycobacterium tuberculosis on cholesterol and 637 modulates intramacrophage signaling More than cholesterol catabolism: regulatory 639 vulnerabilities in Mycobacterium tuberculosis Caseum: a Niche for Mycobacterium tuberculosis Drug-641 Tolerant Persisters EMBO 646 Molecular Medicine Presence of multiple lesion types with vastly 650 different microenvironments in C3HeB/FeJ mice following aerosol infection with 651 Mycobacterium tuberculosis Heterogeneous disease progression 653 and treatment response in a C3HeB/FeJ mouse model of tuberculosis Ipr1 gene mediates innate immunity to tuberculosis Treatment for Drug-Resistnat Tuberculosis Quality control and preprocessing of 663 metagenomic datasets ea-utils: Command-line tools for processing biological sequencing data Lambda Red-mediated recombinogenic engineering of 667 enterohemorrhagic and enteropathogenic E. coli